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Because the Bone Marrow Donor Worldwide Registry (BMDW) now comprises over six million HLA-typed volunteer donors, the chance of identifying an HLA-ABDR serologically identical donor has increased dramatically. 1, 2 As a consequence, in Europe one in four allogeneic transplants is now performed with marrow from an unrelated donor. 3 In the USA over 1200 unrelated BMTs are performed annually through the National Marrow Donor Program. 2 The continuous increase in the numbers of available donors augmented the probability of identifying an HLA-ABDR phenotypically matched donor at the initial search from 10-15% in 1987 to 56% in 1994, 1 70% in 1995 4 to Ͼ90% in 1997. 2 After applying DRB1 high resolution testing an HLA-ABDRB1-matched donor can be found for 40-50% of the patients. 2, [5] [6] [7] Because of the predominance of Caucasoids in most of the national registries, donor searches are more successful for Caucasoid patients while success rates for patients from other ethnic groups are much lower.
Despite these developments, unrelated BMT remains associated with a higher rate of post-transplant complications compared to related BMT. This is probably due to hidden HLA incompatibilities that are targets for alloreactive CTLs. Indeed, we 5, 6, 8 and others 7, [9] [10] [11] [12] have shown that a large fraction of 'ABDR-matched' patient-donor combinations are in fact mismatched at the allelic level when histocompatibility typing techniques with a higher resolution power are applied. Patient/donor matching policies differ from country to country, and may even vary from one centre to another. To date, an effort is made to agree upon guidelines in terms of immunogenetic requirements at the national level. 13, 14 DNA matching of class I and II alleles correlates with increased patient survival. 7, 12, 15, 16 It is clear, however, that the more we demand at the level of HLA matching the less chance there is of identifying a compatible donor. Whenever a highly compatible donor is not found immediately, the decision to accept the mismatch or to continue the search until a fully matched donor is identified would be facilitated considerably if one were able to estimate the chance of success. Detailed reports on single centre or national experiences with a large series of search requests that would allow a precise estimate of the chance of identifying a highly matched unrelated donor may be helpful. 1, 4, [17] [18] [19] This paper reports the Swiss experience in 104 consecutive donor searches from 1995 to 1998.
Patients, donors and search procedure
All searches for patients to be transplanted in one of the four Swiss transplant centres (Division of Haematology, University Hospital, Geneva; Division of Haematology, Kantonsspital, Basel; Division of Haematology, Kantonsspital, Zürich; and Kinderspital, Zürich) are centralised by the Swiss Bone Marrow Donor Registry in Bern. Potential donors are requested in the national registries through BMDW and blood samples are sent to the National Reference Laboratory for Histocompatibility (LNRH) in Geneva. From 1 January 1995 to 31 December 1997, for a total of 104 patients a search has been initiated. The registries of Japan and Taiwan provided donors for two patients of Asian origin. When more than five donors are available through BMDW, our strategy is to initially ask for the blood samples of five donors and decide whether to continue when complete histocompatibility data are available. Histocompatibility testing includes the following: (1) HLA-AB serology (AB120 Biotest and Pelfrez or OneLambda trays); (2) HLA-DR generic DNA typing 20 resolving 50 DRB1/B3/B4/B5 alleles or groups of alleles; (3) High resolution HLA-DRB1/DRB3/DRB5 typing is then performed (by PCR-SSP (Dynal) and/or PCR-SSOP techniques). DRB4 subtyping was not considered because of strong linkage disequilibrium with B and DRB1 alleles; 21 (4) HLA class I PCR-SSO or PCR-SSP subtyping of HLA-A2, A3, B35, and B44 antigens, that comprise over 90% of A/B subtype mismatches; 6, 22, 23 (5) HLA-C and DQB1 typing are performed by PCR-SSOP or PCR-SSP; 8 (6) Those donors that show full HLA compatibility are finally tested by the in vitro CTLpf analysis; 6 Searches initiated during the 3-year period (1995) (1996) (1997) were continued until December 1998, when a total of 461 blood samples had been analyzed.
Results

Potential donors identified in 104 consecutive searches
From 1 January 1995 to 31 December 1998, we received a total of 461 donor blood samples for 86 of the 104 patients (82.7%) for whom a search was initiated between 1995 and 1997. For the remaining 18 patients, donors were not tested for the following reasons: for eight patients (7.7%), no HLA-ABDR matched donor was found on the BMDW file. Five patients for whom donors would have been available died before the blood sample was shipped and for five other patients, the search was interrupted for clinical reasons or because the patient decided against being transplanted. Of the 461 donors from whom a blood sample was tested, 41 donors (8.9%) were eliminated after a first serological confirmatory typing of HLA-AB antigens either due to undetected antigens, extra-reactions (26 donors, 5.6%), or to serological split mismatches (15 donors, 3.3%) mainly within A19 and B40. After HLA-DR generic typing, another 30 donors (7.2%) were eliminated on the basis of either an incorrect assignment of DR1-DR10 serotypes (20 donors, 4.8%) or due to split antigen (DR15 vs DR16, and DR13 vs DR14) mismatches (10 donors, 2.4%). Thus, due to incorrect assignment of generic HLA-AB or -DR antigens or to missing split antigens, 15.4% (71/461) of the recruited donors had to be discarded. Table 1 shows grade of compatibility of the best matched donor available for each patient. For 33 (38.4%) patients, at least one highly compatible donor (4.5 donors tested/patient, range 1-13) was identified. For five patients, the best matched donor was ABCDRB1/B3/B5-matched, but DQ-mismatched. Thus, a total of 44.2% of the patients had an HLA-ABCDRB1/B3/B5-allele matched (CTLpnegative) donor. Not unexpectedly, Cw was the incompatibility most frequently found in the other ABDR-matched pairs. 4, 8, 10, 11 For 17 (19.8%) patients (average of 5.5, range 1-14 donors tested/patient), the best matched donor was A/B/DRB1/B3/B5-allele matched, Cw-incompatible. Fully HLA-A/B/DRB1/B3/B5-compatible donors with a single DRB3 mismatch were identified for four patients (4.6%) with an average of 8.3 donors tested/patient (range 2-10). In two cases, the DRB3 disparity was accompanied by a Cw mismatch.
A highly matched donor is available for 38% of the patients for whom at least one ABDR-matched donor is recruited
For the remaining 27 patients (31.4%), no donors matched at the level mentioned above were found (average six donors tested/patient, range 1-20). All donors were incompatible for either HLA-A, and/or -B, and/or DRB1 alleles (Table 1) . Class I mismatches were either at the level of a serological split (eg A66 vs A25 or A26), or most frequently, at the allelic level (A2, B35 and B44-subtypes) while DR4-subtypes represented the bulk of the class II mismatches.
As reported by others 17 the probability of identifying a highly matched donor was associated with the patient's HLA-ABDR phenotype frequency. Indeed, for 12 of 18 patients who had at least one frequent (F Ͻ 1%) haplotype, a donor matched at the allelic level was identified after testing an average of five blood samples only.
Is it worthwhile to continue the search when the first donors recruited are not fully compatible?
We have evaluated the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-identical donor for those patients for whom none of the first five donors tested were highly compatible. To be able to analyze a reasonable number, we included all patients from 1992 on (n = 50). Table 2 shows that for only four patients, was the sixth donor recruited highly compatible. Searches were continued for 37 patients (two patients received an alternative transplant, three patients died and four searches were discontinued for clinical reasons and/or lack of additional ABDR-matched donors on the BMDW file). For four other patients, the seventh donor was fully matched. The time needed to identify these donors had increased from an average of 156 days typical for a patient with a compatible donor among the first five tested, to an average of 270 days. Thus, depending on the clinical status of the patient, it might be worthwhile continuing the search even when the first five donors are mismatched. However, after seven donors have been tested, this strategy appears to be less worthwhile. As shown in Table 2 , we recruited only two additional fully matched donors for the 29 patients for whom we continued the search. For one patient, the ninth donor recruited 491 days after the start of the search was compatible while for another, only the 12th donor, identified after 560 days, was matched. For all the other 27 patients, no compatible donor was found, even if more than 20 ABDR-matched donors were tested. Table 2 Probability of identifying a highly matched donor for patients without a matched donor among the first five tested 
Matching category No. of pairs (%)
HLA
Matching status/search time of the transplanted patients
Of the 86 patients for whom at least one donor blood sample was typed during 1995-1998, a total of 40 patients (46.5%) have been transplanted. Twenty-two patients received marrow from an HLA-A/B/Cw/DRB1/ B3/B5/DQB1-identical, CTLp-negative donor (Table 3) . Seventeen patients received marrow from a donor with a single incompatibility, either for Cw (25%), for A (2.5%), for DQB1 (10%) or for DRB3 (5%). The average time between the start of the search and the transplant was approximately 7 months. Figure 1 shows that it took an average of 45 (21-101) days before the first donor could be tested. Twenty-four (0-224) days later, the final donor was identified. After another 54 days needed to perform confirmatory ABDR typing, all molecular biology tests, as well as the in vitro CTLpf analysis, the results were sent to the clinician to decide whether the transplant should proceed.
Discussion
The chance of identifying an 'HLA-compatible' unrelated donor depends on how 'HLA-compatible' or 'fully matched' is defined. It is our current policy to aim for an A/B/Cw/DRB1/B3/B5/DQB1-allele matched (CTLpnegative) donor. 24 Due to the extremely high rates of DPmismatches, 4, 5, 10, 25 this locus is not taken into account. Between 1995 and 1998, this strategy identified 'fully matched' donors for 38.4% of the patients for whom a search was started. In addition, for another 30.2% patients, a donor with only a DRB3-, DQ-or Cw-disparity (with a moderately positive CTLp) was available. Compared to our previous experience from 1990 to 1992, 18 the success rate of the search procedures is much higher, despite the fact that the number of allelic subtypes tested for has significantly increased. 26 This is mainly due to the larger number of registered volunteer donors (Ͼ6 million donors in BMDW) and to the increased HLA subtyping of the donors. This has allowed the identification of an ABDR-serologically identical donor for 92.2% of the patients, which is 1.5-3 times higher than 5-10 years ago. 18, 27, 28 It is interesting to note that the recently discovered HLA allelic subtypes 26 did not have a major impact on patient/donor matching. Among the 104 patients and 461 donors analyzed in this study, we have not encountered any DR11 or DR13 alleles other than the common DRB1* 1101/1102/1103/1104 and 1301/1302/1303 alleles, whereas 60 DR11 and DR13 subtypes are described to date. 26 An important observation from our analysis was that one of seven donors recruited (15%) had been inappropriately selected either because of a wrong serological assignment, or because serological splits of A19, B40, DR2, DR5, and DR6 had not been determined by the donor registry. Therefore, we suggest that registries give first priority to correct assignment of the DR1 to DR18 generic specificities and of A, B-serological splits, before performing high resolution DRB1, DQ or class I subtyping.
From a total of 86 patients for whom at least one unrelated bone marrow donor was actually tested, 46% were transplanted. This is higher than our previous 1990-1992 experience, but in agreement with the more recent Dutch data. 4 The most remarkable improvement was the fact that 55% of the patients who were transplanted did benefit from a highly compatible donor. Therefore, it is clear that even by applying the most stringent matching criteria, there is still a reasonable chance of identifying a compatible donor within a time-frame of about 4 months.
